JP2018537484A - 肝内胆汁うっ滞および関連肝疾患の治療 - Google Patents

肝内胆汁うっ滞および関連肝疾患の治療 Download PDF

Info

Publication number
JP2018537484A
JP2018537484A JP2018530858A JP2018530858A JP2018537484A JP 2018537484 A JP2018537484 A JP 2018537484A JP 2018530858 A JP2018530858 A JP 2018530858A JP 2018530858 A JP2018530858 A JP 2018530858A JP 2018537484 A JP2018537484 A JP 2018537484A
Authority
JP
Japan
Prior art keywords
composition
activity
use according
subject
strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018530858A
Other languages
English (en)
Japanese (ja)
Inventor
カールソン、フレドリック
メルスタム、ボー
Original Assignee
メタボゲン アーベー
メタボゲン アーベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メタボゲン アーベー, メタボゲン アーベー filed Critical メタボゲン アーベー
Publication of JP2018537484A publication Critical patent/JP2018537484A/ja
Priority to JP2022120558A priority Critical patent/JP2022166039A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2018530858A 2015-12-14 2016-12-14 肝内胆汁うっ滞および関連肝疾患の治療 Pending JP2018537484A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022120558A JP2022166039A (ja) 2015-12-14 2022-07-28 肝内胆汁うっ滞および関連肝疾患の治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562266771P 2015-12-14 2015-12-14
US62/266,771 2015-12-14
PCT/EP2016/080941 WO2017102816A1 (en) 2015-12-14 2016-12-14 Treatment of intrahepatic cholestasis and related liver diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022120558A Division JP2022166039A (ja) 2015-12-14 2022-07-28 肝内胆汁うっ滞および関連肝疾患の治療

Publications (1)

Publication Number Publication Date
JP2018537484A true JP2018537484A (ja) 2018-12-20

Family

ID=57570064

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018530858A Pending JP2018537484A (ja) 2015-12-14 2016-12-14 肝内胆汁うっ滞および関連肝疾患の治療
JP2022120558A Abandoned JP2022166039A (ja) 2015-12-14 2022-07-28 肝内胆汁うっ滞および関連肝疾患の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022120558A Abandoned JP2022166039A (ja) 2015-12-14 2022-07-28 肝内胆汁うっ滞および関連肝疾患の治療

Country Status (16)

Country Link
US (1) US20180369297A1 (https=)
EP (1) EP3389680B1 (https=)
JP (2) JP2018537484A (https=)
KR (1) KR20180094950A (https=)
CN (1) CN109069548A (https=)
AU (1) AU2016374365B2 (https=)
BR (1) BR112018012022A2 (https=)
CA (1) CA3008195A1 (https=)
CL (1) CL2018001548A1 (https=)
ES (1) ES2962302T3 (https=)
IL (1) IL259480B2 (https=)
MX (1) MX2018007227A (https=)
RU (1) RU2743405C2 (https=)
SG (1) SG11201804255QA (https=)
WO (1) WO2017102816A1 (https=)
ZA (1) ZA201804660B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023176951A1 (ja) 2022-03-18 2023-09-21 株式会社明治 Ｃｏｌｌｉｎｓｅｌｌａ属細菌の増殖制御用組成物及びその利用
JP2024506052A (ja) * 2021-02-08 2024-02-08 リスキュア・バイオサイエンシーズ・カンパニー・リミテッド ロイコノストック・シトレウム菌株を有効成分として含む胆汁うっ滞性肝疾患の予防または治療用医薬組成物
JP7852936B2 (ja) 2021-02-08 2026-04-28 リスキュア・バイオサイエンシーズ・カンパニー・リミテッド ロイコノストック・シトレウム菌株を有効成分として含む胆汁うっ滞性肝疾患の予防または治療用医薬組成物

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
CA3212215A1 (en) 2012-11-23 2014-05-30 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
EP2967077A4 (en) 2013-03-15 2016-09-14 Seres Therapeutics Inc NETWORK-BASED MICROBIAL COMPOSITIONS AND METHOD
SG10201903823QA (en) 2014-10-31 2019-05-30 Whole Biome Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
EP3668527A1 (en) * 2017-08-14 2020-06-24 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
CN111372596A (zh) 2017-08-30 2020-07-03 潘德勒姆治疗公司 用于治疗微生物组相关病症的方法和组合物
JP2021501185A (ja) 2017-10-30 2021-01-14 セレス セラピューティクス インコーポレイテッド 抗生物質耐性を処置するための組成物及び方法
CA3106315A1 (en) 2018-07-19 2020-01-23 Pendulum Therapeutics, Inc. Methods and compositions for microbial engraftment
EP3870691A4 (en) 2018-09-13 2022-09-07 Xbiome Inc. METHODS AND COMPOSITIONS FOR TREATING GASTROINTESTINAL AND INFLAMMATORY DISORDERS
CN112280720B (zh) * 2020-11-19 2021-07-13 山东龙昌动物保健品有限公司 一株多形拟杆菌gl-02及其与胆汁酸复配的复合菌剂与应用
GB2628547A (en) * 2023-03-27 2024-10-02 Univ Newcastle Probiotic and postbiotic compositions, products and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000071138A2 (en) * 1999-05-25 2000-11-30 Gregor Reid Oral administration of lactobacillus for the maintenance of health in women

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1283225B1 (it) * 1996-03-11 1998-04-16 Renata Maria Anna Ve Cavaliere Ceppi di batteri, composizione farmaceutica contenente uno o piu' di tali ceppi e uso dei medesimi per la prevenzione e la terapia delle
AUPQ899700A0 (en) * 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
CA2642431A1 (en) * 2006-02-15 2007-08-23 Nestec S.A. Use of bifidobacterium longum for the prevention and treatment of inflammation
US20120128633A1 (en) * 2009-04-30 2012-05-24 Campagnie Gervaise Donone Use of collinsella aerofaciens for reducing bloating
CN102539791A (zh) * 2012-01-09 2012-07-04 宁波天康生物科技有限公司 总胆汁酸的定量测定及测定试剂盒
AU2014331610B2 (en) * 2013-10-03 2019-11-07 Trustees Of The University Of Pennsylvania Compositions comprising a defined microbiome and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000071138A2 (en) * 1999-05-25 2000-11-30 Gregor Reid Oral administration of lactobacillus for the maintenance of health in women

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FEMS MICROBIOL. LETT., (2004), 235, [1], P.65-72, JPN7020004038, ISSN: 0004577166 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024506052A (ja) * 2021-02-08 2024-02-08 リスキュア・バイオサイエンシーズ・カンパニー・リミテッド ロイコノストック・シトレウム菌株を有効成分として含む胆汁うっ滞性肝疾患の予防または治療用医薬組成物
JP7852936B2 (ja) 2021-02-08 2026-04-28 リスキュア・バイオサイエンシーズ・カンパニー・リミテッド ロイコノストック・シトレウム菌株を有効成分として含む胆汁うっ滞性肝疾患の予防または治療用医薬組成物
WO2023176951A1 (ja) 2022-03-18 2023-09-21 株式会社明治 Ｃｏｌｌｉｎｓｅｌｌａ属細菌の増殖制御用組成物及びその利用

Also Published As

Publication number Publication date
RU2018124487A (ru) 2020-01-10
EP3389680C0 (en) 2023-10-11
EP3389680A1 (en) 2018-10-24
SG11201804255QA (en) 2018-06-28
IL259480B2 (en) 2023-09-01
JP2022166039A (ja) 2022-11-01
WO2017102816A1 (en) 2017-06-22
ZA201804660B (en) 2022-12-21
CN109069548A (zh) 2018-12-21
BR112018012022A2 (pt) 2018-12-04
RU2018124487A3 (https=) 2020-05-29
RU2743405C2 (ru) 2021-02-18
IL259480B1 (en) 2023-05-01
CL2018001548A1 (es) 2018-07-20
CA3008195A1 (en) 2017-06-22
US20180369297A1 (en) 2018-12-27
AU2016374365A1 (en) 2018-07-12
AU2016374365B2 (en) 2023-04-13
MX2018007227A (es) 2018-08-01
ES2962302T3 (es) 2024-03-18
KR20180094950A (ko) 2018-08-24
EP3389680B1 (en) 2023-10-11
IL259480A (en) 2018-07-31

Similar Documents

Publication Publication Date Title
RU2743405C2 (ru) Лечение внутрипеченочного холестаза и родственных заболеваний печени
Soderborg et al. Microbial transmission from mothers with obesity or diabetes to infants: an innovative opportunity to interrupt a vicious cycle
Nieuwdorp et al. Role of the microbiome in energy regulation and metabolism
Ahmadi et al. The effects of synbiotic supplementation on markers of insulin metabolism and lipid profiles in gestational diabetes: a randomised, double-blind, placebo-controlled trial
Javadi et al. The effect of probiotic and/or prebiotic on liver function tests in patients with nonalcoholic fatty liver disease: a double blind randomized clinical trial
Hamad et al. Milk fermented by Lactobacillus gasseri SBT2055 influences adipocyte size via inhibition of dietary fat absorption in Zucker rats
Oka et al. A multi-center double-blind controlled trial of ursodeoxycholic acid for primary biliary cirrhosis
US20220378809A1 (en) Synthetic composition for balancing the bile acid profile in the intestine
Thomson Small intestinal disorders in the elderly
Górowska-Kowolik et al. The role of gut micorbiome in obesity and diabetes
Winzell et al. Temporal and dietary fat content–dependent islet adaptation to high-fat feeding–induced glucose intolerance in mice
CN102014960A (zh) 基于护肝剂和益生元的药物组合物、其制备及其应用
CN110418836A (zh) 用于预防性或治疗性治疗肝疾病的组合物
FALOON Metabolic effects of nonabsorbable antibacterial agents
Josyabhatla et al. Pediatric intestinal failure and the microbiome
HK40002061A (en) Treatment of intrahepatic cholestasis and related liver diseases
JPWO2021094993A5 (https=)
King et al. Lithocholic acid, cholestasis, and liver disease
Colombo et al. Delayed intestinal visualization at hepatobiliary scintigraphy is associated with response to long-term treatment with ursodeoxycholic acid in patients with cystic fibrosis-associated liver disease
Diamond et al. Advantages of the distal sigmoid colostomy in the management of infants with short bowel syndrome
Nagengast Dietary fibre and bile acid metabolism
Parekh et al. The Role of Gut Microflora in Obesity-Does the Data Provide an Option for Intervention?
Jiang et al. Clinical efficacy of phenobarbital combined with ursodeoxycholic acid in the treatment of neonatal patients with cholestasis
Sauter et al. Effect of dietary fiber on serum bile acids in patients with chronic cholestatic liver disease under ursodeoxycholic acid therapy
CN120227389A (zh) 一种猴菇多糖的用途

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211122

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220728

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220729

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220819

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220913

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220914

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20221007

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20221012